Background: Chronic inflammatory responses are involved in the initiation and development of the coronary slow flow phenomenon (CSFP). However, as a newly developed immuno-nutritional inflammation indicator, the global immune-nutrition inflammation index (GINI) has not been well elaborated for predicting CSFP in patients with angina and no obstructive coronary arteries (ANOCA).
Methods: A total of 1422 individuals with ANOCA were consecutively included in this study, of whom 93 developed CSFP (CSFP group). We selected 186 (1:2 matched) age- and sex-matched patients with ANOCA and angiographically proven normal coronary blood flow as the controls (the control group). Multivariate logistic regression analysis was used to investigate predictors of CSFP in patients with ANOCA. The optimal cutoff values for GINI were calculated.
Results: In total, 93 patients developed CSFP, including 29% (27) in one vessel, 28% (26) in two vessels, and 43% (40) in three vessels. Patients with CSFP had an elevated CRP level, white blood cell (WBC) count, neutrophil count, GINI, fasting blood glucose (FBG) level, and a lower lymphocyte count (P<0.05). Multivariate logistic analysis showed that the GINI and FBG levels were independent predictors of CSFP in patients with ANOCA. Moreover, we found that the more vessels affected by CSFP, the higher the GINI level. The receiver operating characteristic (ROC) showed that GINI had a better predictive value than indicators alone. When the GINI AISI was >84.1, the sensitivity and specificity were 88.2% and 58.7%, respectively [The Area Under the ROC curve (AUC): 0.774; 95% CI: 0.721-0.827; P < 0.001].
Conclusion: Elevated GINI is a reliable predictor of CSFP in patients with ANOCA. Moreover, GINI had a superior predictive value compared to the indicators alone. As a newly developed inflammatory indicator, GINI can be used for further risk stratification of patients with ANOCA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895676 | PMC |
| http://dx.doi.org/10.2147/IJGM.S516108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Global Immune-Nutrition Inflammation Index for Predicting Coronary Slow Flow Phenomenon in Patients with Angina and No Obstructive Coronary Arteries.
Int J Gen Med
March 2025
Department of Intensive Care Unit, Shenzhen Luohu Hospital Group Luohu People's Hospital (The Third Affiliated Hospital of Shenzhen University), Shenzhen, People's Republic of China.
Background: Chronic inflammatory responses are involved in the initiation and development of the coronary slow flow phenomenon (CSFP). However, as a newly developed immuno-nutritional inflammation indicator, the global immune-nutrition inflammation index (GINI) has not been well elaborated for predicting CSFP in patients with angina and no obstructive coronary arteries (ANOCA).
Methods: A total of 1422 individuals with ANOCA were consecutively included in this study, of whom 93 developed CSFP (CSFP group).
Rationale and Design of the ILIAS ANOCA Clinical Trial: a blinded-arm controlled trial for routine ad-hoc coronary function testing.
Am Heart J
March 2025
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address:
Angina with non-obstructive coronary arteries (ANOCA) is a major cause of chronic coronary syndromes, affecting nearly half of patients with anginal symptoms who undergo invasive coronary angiography. ANOCA may lead to substantial symptom burden, increased risk of adverse cardiac events, increased healthcare utilization due to ongoing symptoms, repeat hospitalizations, and invasive testing. The pathophysiology of ANOCA often involves a variety of coronary disorders, such as coronary microvascular dysfunction, epicardial or microvascular vasospasm and endothelial dysfunction.
View Article and Find Full Text PDFIschemia with no obstructed coronary arteries and microvascular testing procedures: a review of utility, pharmacotherapy, and current challenges.
Front Cardiovasc Med
February 2025
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Ischemia with no obstructive coronary arteries (INOCA) is an increasingly recognized condition in patients presenting with angina and positive stress tests but without significant coronary artery stenosis. This review addresses the pathophysiology, diagnostic approaches, and management strategies associated with INOCA, emphasizing epicardial coronary spasms and coronary microvascular dysfunction (CMD) as underlying mechanisms and myocardial bridging (MB) as a risk factor. Diagnostic modalities include both non-invasive techniques and invasive procedures, such as acetylcholine provocation testing, to differentiate vasospasm from microvascular causes.
View Article and Find Full Text PDFParoxysmal Atrial Fibrillation during Spasm Provocation Test with Acetylcholine: Clinical Characteristics of Patients and Effect on Coronary Microvascular Function Measurements.
Rev Cardiovasc Med
February 2025
Department of Cardiovascular Medicine, JR Hiroshima Hospital, 732-0057 Hiroshima, Japan.
Background: Atrial fibrillation (AF) is a complication that occurs following a spasm provocation test (SPT) with acetylcholine (ACh). However, the characteristics of patients with AF remain unclear. Furthermore, the association of AF with the outcome of the coronary microvascular function test (CMFT) is unknown.
View Article and Find Full Text PDFEfficacy and safety of Shexiang Baoxin Pill in patients with angina and non-obstructive coronary arteries: A multicenter, randomized, double-blind, placebo-controlled, phase Ⅳ clinical trial.
Phytomedicine
April 2025
Department of Cardiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, PR China; Shanghai Cardiovascular Institute of Integrative Medicine, Shanghai 200003, PR China. Electronic address:
Introduction: Solid evidence generated from large studies supporting the recommendation of Shexiang Baoxin Pill (MUSKARDIA) as a promising treatment for angina and nonobstructive coronary arteries (ANOCA) populations is lacking.
Objective: To evaluate the efficacy and safety of MUSKARDIA in patients with ANOCA.
Methods: In this randomized, double-blind, placebo-controlled, phase IV trial, we enrolled 239 patients with ANOCA at 11 centers across China between May 2021 and July 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!